摘要
Objective： To assess the efficacy of the Coronary Heart Disease （CHD） Capsules worked out by Prof. Deng -- in improving quality of life of CHD patients of qi deficiency with phlegm and blood stasis syndrome. Method： According to the WHO＇s diagnosis criteria of CHD, a total of 93 stable angina patients were divided into 3 groups using the single blinded method. The groups were evenly distributed into CHD Capsule treated group （CHDC）, isosorbide dinitrate control group （ID）, and Compound Prescription Danshen Droplet Pills control group （CPDDP）. Two courses of treatment lasting for 6 months were given. During the courses of treatment, the following parameters were observed： clinical symptoms of angina pectoris, ECG change, treadmill exercise test, 36 items in short form of health survey （SF-36） and Seattle Angina Questionnaire （SAQ） scale. Results： After 6 months of treatment, all the three groups showed good curative effect in angina pectoris, ECG and treadmill exercise test, differences between them had no statistical significance. The CHDC group showed a better result in nitro-glycerine stopping or alleviation rate and in improving symptoms than the other groups （P〈0.05）. The general health, vitality, role-emotional, mental health and reported health transition in the CHDC group were significantly better than those in the control groups （P〈 0.05）. The scores in physiological functioningrole, physiological function and pain alleviation were not different among the three groups. Conclusion. Prof. DENG Tie-tao＇s CHDC is effective in treating CHD with qi deficiency, phlegm and blood stasis and also in improving the quality of life. CHDC is more suitable to be used in long-term treatment than isosorbide dinitrate. The SF-36 and SAQ can be used to appraise the curative effect of traditional Chinese medicine agents for CHD angina pectoris.
Objective： To assess the efficacy of the Coronary Heart Disease （CHD） Capsules worked out by Prof. Deng -- in improving quality of life of CHD patients of qi deficiency with phlegm and blood stasis syndrome. Method： According to the WHO＇s diagnosis criteria of CHD, a total of 93 stable angina patients were divided into 3 groups using the single blinded method. The groups were evenly distributed into CHD Capsule treated group （CHDC）, isosorbide dinitrate control group （ID）, and Compound Prescription Danshen Droplet Pills control group （CPDDP）. Two courses of treatment lasting for 6 months were given. During the courses of treatment, the following parameters were observed： clinical symptoms of angina pectoris, ECG change, treadmill exercise test, 36 items in short form of health survey （SF-36） and Seattle Angina Questionnaire （SAQ） scale. Results： After 6 months of treatment, all the three groups showed good curative effect in angina pectoris, ECG and treadmill exercise test, differences between them had no statistical significance. The CHDC group showed a better result in nitro-glycerine stopping or alleviation rate and in improving symptoms than the other groups （P〈0.05）. The general health, vitality, role-emotional, mental health and reported health transition in the CHDC group were significantly better than those in the control groups （P〈 0.05）. The scores in physiological functioningrole, physiological function and pain alleviation were not different among the three groups. Conclusion. Prof. DENG Tie-tao＇s CHDC is effective in treating CHD with qi deficiency, phlegm and blood stasis and also in improving the quality of life. CHDC is more suitable to be used in long-term treatment than isosorbide dinitrate. The SF-36 and SAQ can be used to appraise the curative effect of traditional Chinese medicine agents for CHD angina pectoris.
基金
SupportedbyDepartmentofScienceandTechnologyofGuangdongProvince'sDocument(No.281)
